多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效评价

张伟娜 黄晓华

摘要：目的  探討多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效。方法  选取2017年4月～2018年4月我院收治的晚期卵巢癌患者中76例，随机分为观察组和对照组，每组38例。对照组仅接受多西他赛静脉化疗治疗，观察组接受多西他赛联合洛铂腹腔灌注治疗。对比两组临床疗效，并观察治疗后患者糖类多肽抗原（CA125）、血清人附睾分泌蛋白4（HE4）水平以及不良反应发生情况。结果  观察组治疗总有效率为97.37%，高于对照组的84.21%，差异具有统计学意义（P<0.05）。观察组治疗后CA125水平为（31.19±14.28）kU/L、HE4水平为（93.71±23.69）pmol/L，均低于对照组的（49.86±17.52）kU/L、（158.62±31.47）pmol/L，差异具有统计学意义（P<0.05）。观察组总不良反应发生率为13.16%，低于对照组的28.95%，差异具有统计学意义（P<0.05）。结论  晚期卵巢癌患者接受多西他赛联合洛铂腹腔灌注治疗效果更为理想，极大的改善了各功能指标，降低了不良反应发生率，临床实用价值较高。

关键词：多西他赛;洛铂;腹腔灌注;晚期卵巢癌

中图分类号：R737.31                                文献标识码：A                                 DOI：10.3969/j.issn.1006-1959.2019.08.047

文章编号：1006-1959（2019）08-0154-03

Abstract：Objective  To investigate the clinical efficacy of docetaxel combined with lobaplatin in the treatment of patients with advanced ovarian cancer. Methods  76 patients with advanced ovarian cancer admitted to our hospital from April 2017 to April 2018 were randomly divided into observation group and control group， 38 cases in each group. The control group received only docetaxel intravenous chemotherapy， and the observation group received docetaxel plus lobaplatin intraperitoneal perfusion. The clinical efficacy of the two groups was compared， and the levels of carbohydrate polypeptide （CA125）， serum human epididymal secretory protein 4 （HE4） and adverse reactions were observed. Results  The total effective rate of the observation group was 97.37%， which was higher than that of the control group 84.21%，the difference was statistically significant （P<0.05）. The CA125 level of the observation group was （31.19±14.28） kU/L and the HE4 level was （93.71±23.69） pmol/L， which was lower than that of the control group （49.86±17.52） kU/L， （158.62±31.47） pmol/L， the difference was statistically significant （P<0.05）. The incidence of total adverse reactions was 13.16% in the observation group， which was lower than that in the control group 28.95%，the difference was statistically significant （P<0.05）. Conclusion  The treatment of patients with advanced ovarian cancer with docetaxel combined with lobaplatin is more ideal， which greatly improves the functional indicators， reduces the incidence of adverse reactions， and has higher clinical value.

Key words：Docetaxel;Lobaplatin;Intraperitoneal perfusion;Advanced ovarian cancer